VS-041

Phase 1Small molecule

VS-041 is one of 2 small molecule programs targeting Heart Failure With Preserved Ejection Fraction (HFPEF). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart Failure With Preserved Ejection Fraction (HFPEF)Active, not recruiting

Heart Failure With Preserved Ejection Fraction (HFPEF)Phase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Heart Failure With Preserved Ejection Fraction (HFPEF)

#DrugCompanyPhaseTrials

CK-4021586

CCytokinetics

Phase 2

1 2

VS-041

VVasa Therapeutics

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Heart Failure With Preserved Ejection Fraction (HFPEF)

NCT07219511

Clinical

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction (HFPEF)1 trial

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruiting·VVasa Therapeutics·Phase 1·NCT07219511·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for VS-041. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VS-041 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VS-041. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vasa Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVasa Therapeutics

VS-041

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Heart Failure With Preserved Ejection Fraction (HFPEF)1 trial

References

Drug Info

Quick Facts

Related News